HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kung, H. F. Articles by Reilley, J. Search for Related Content PubMed PubMed Citation Articles by Kung, H. F. Articles by Reilley, J.

In Vivo SPECT Imaging of CNS D-2 Dopamine Receptors: Initial Studies with Iodine-123-IBZM in Humans

Division of Nuclear Medicine, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
Division of Nuclear Medicine, Department of Radiology, Georgetown University Hospital, Washington, DC

Correspondence: For reprints contact: Hank F. Kung, MD, Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce St., Philadelphia, PA 19104.

ABSTRACT

Iodobenzamide (IBZM) is a D-2 dopamine receptor antagonist. In this paper the results of Phase I clinical studies of iodine-123- (¹²³I)IBZM in humans are reported. Preliminary imaging studies, both planar and single-photon emission tomography (SPECT), of no-carrier added [¹²³I]IBZM in humans show specific localization in the basal ganglia of the brain. At 2 hr after an i.v. injection, the brain uptake was 3.72% of the dose, and at 20 hr later the uptake diminished to 0.7%. Radiation dosimetry calculation indicated that the radiation dose to the brain was minimum, 0.039 rad/mCi, while the large intestine wall received the highest dose, 0.28 mrad/mCi. The radiation dosimetry and pharmacology data suggest that this agent is safe for human use.

This article has been cited by other articles:

				T. F. Massoud and S. S. Gambhir Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes & Dev., March 1, 2003; 17(5): 545 - 580. [Full Text] [PDF]

				P. Seeman and T. Tallerico Rapid Release of Antipsychotic Drugs From Dopamine D2 Receptors: An Explanation for Low Receptor Occupancy and Early Clinical Relapse Upon Withdrawal of Clozapine or Quetiapine Am J Psychiatry, June 1, 1999; 156(6): 876 - 884. [Abstract] [Full Text]